65th ASH Annual Meeting & Exposition: 802. Chemical Biology and Experimental Therapeutics: Poster I

Symposia: Chemical Biology and Experimental Therapeutics Oral and Poster Abstracts
Poster

Halls G-H (San Diego Convention Center)

The Novel Profiling Relative Inhibition Simultaneously in Mixtures (PRISM) Platform Identifies Synergistic Activity of Lanraplenib and Ruxolitinib in Hematological Malignancies

Akanksha Pandey, PhD¹^*, Luis A. Carvajal, PhD²^*, Andrew S Boghossian, BS³^*, Matthew G Rees, DPhil³^*, Melissa M Ronan, MS³^*, Jennifer A Roth, MS, MBA³^*, Tressa Hood, MS¹^*, Linlin Guo, PhD¹^*, Tamara D Hopkins, PhD¹^*, Nikolaus Obholzer, PhD¹^*, Michael R. McKeown, PhD¹^*, Jorge F. DiMartino, MD² and Charles Y. Lin, PhD¹^*

¹Kronos Bio, Inc., Cambridge, MA
²Kronos Bio, Inc., San Mateo, CA
³Broad Institute of MIT and Harvard, Cambridge, MA

2260

The PKC-β Inhibitor MS-553 Displays Preclinical Efficacy in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia

Britten Gordon, BS¹, Elizabeth Muhowski, PhD²^*, Janani Ravikrishnan, PhD³^*, Shanmugapriya Thangavadivel, PhD⁴^*, Samon Benrashid, BS¹^*, Alexander He, BS¹^*, Shrilekha Misra, PhD¹^*, Tzung-Huei Lai, PhD¹^*, Alexander Marr, BS¹^*, Lianbo Yu, PhD¹^*, Brandi Walker, BS¹^*, Elizabeth Perry, BS¹^*, Nicole R. Grieselhuber, MD, PhD¹, Kerry A Rogers, MD⁴, James S. Blachly⁵, Adam S Kittai, MD⁴, Seema A Bhat, MD⁴, John C. Byrd, MD⁶, Michael Niesman, PhD⁷^*, Kai Zhang, MD⁸^*, Deepa Sampath, PhD⁹ and Jennifer A. Woyach, MD³

¹The Ohio State University, Columbus, OH
²Comprehensive Cancer Center, The Ohio State University, Columbus, OH
³The Ohio State University Comprehensive Cancer Center, Columbus, OH
⁴Division of Hematology, The Ohio State University, Columbus, OH
⁵Department of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH
⁶Department of Internal Medicine, University of Cincinnati, Cincinnati, OH
⁷MingSight Pharmaceuticals, San Diego, CA
⁸MingSight Pharmaceuticals, Irmo, CA
⁹Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX

2261

Selective Targeting of TP53-Y220C Mutant AML By PC14586 Results in TP53 Wild-Type Conformation and Synergistical Apoptosis Induction By Concomitant Inhibition of Xpo-1, MDM2, or Bcl-2

Bing Z. Carter, PhD¹, Po Yee Mak¹^*, Baozhen Ke¹^*, Yuki Nishida, MD, PhD¹, Steffen Boettcher, MD²^*, Andrea Bedoy¹^*, Lauren B. Ostermann, BSc¹^*, Courtney D. DiNardo, MD, MSc³, Anna Puzio-Kuter⁴^*, Arnold Levine⁵^* and Michael Andreeff, MD PhD³

¹Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²University Hospital Zurich, Zurich, Zurich, Switzerland
³Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴PMV Pharmaceuticals, Inc, Princeton, NJ
⁵Institute for Advanced Studies, Princeton

2262

Novel Orally Available Degrader to Target Lck in T-Cell Acute Lymphoblastic Leukemia

Na-Rae Jeong¹^*, Ye Seul Lim¹^*, Sun-Mi Yoo²^*, Han Wool KIM¹^*, So Hyuk Kim¹^*, Ae-Ran Choi¹^*, Dong-Wook Kim, MD, PhD³ and Song Hee Lee, PhD¹^*

¹Ubix therapeutics, Seoul, Korea, Republic of (South)
²Ubix therapeutics, Seoul, South Korea
³Uijeongbu Eulji Medical Center, Uijeoungbu-si, Korea, Republic of (South)

2263

EP102: Pharmacological Inhibition of METTL3 Elicits Tumor Growth Inhibition In Vivo

and Demonstrates Synergy with Venetoclax in Various AML Models

Graeme Fraser¹^*, Catherine Sorlet²^*, Nicolas Parmentier²^*, Anne-France Hartiel²^*, Sandrine Hospied²^*, Clement Mompied²^*, Genevieve Absil²^*, Killian Oukoloff²^* and Guillaume Dutheuil²^*

¹EPICS SA, Gosselies, AL, Belgium
²EPICS SA, Gosselies, Belgium

2264

Inhibition of MET Tyrosine Kinase Provides a Strategy for Targeting the Inflammatory Tumor Microenvironment

Maura Lima Pereira Bueno, UR¹^*, Irene Santos, PhD¹^*, Nádia Ghinelli Amôr, PhD¹^*, Adriana Duarte da Silva Santos, PhD¹^*, Audrey Bastos¹^*, Karla Priscila Ferro, PhD²^*, Sara Teresinha Olalla Saad, MD¹ and Fernanda Marconi Roversi, PhD^1,3^*

¹Hematology and Transfusion Medicine Center - University of Campinas/Hemocentro-UNICAMP, Campinas, São Paulo, Brazil
²Hematology and Transfusion Medicine Center - University of Campinas / Hemocentro - UNICAMP, Campinas, São Paulo, Brazil, Campinas, Brazil
³Department of Surgery, Emory University, Atlanta, Georgia, USA., Atlanta, GA, Brazil

2265

BGS-2456 Is a Novel Potent Covalent Inhibitor of FLT3 That Highly Discriminates Against KIT and Is Not Toxic Toward Normal Hematopoiesis in Vitro

Ariel Leyte-Vidal, BS^1,2, Stacey Phan, BS¹^*, Prachi Khare, MS¹^*, FeiFei Hu, MS¹^*, Chao Zhang, PhD³^*, Ping Cao, PhD⁴^* and Neil P. Shah, MD, PhD¹

¹University of California, San Francisco, CA
²University of Miami, Miami, FL
³University of Southern California, Los Angeles, CA
⁴Bridgene Biosciences, San Jose, CA

2266

CDK12/13: A Promising New Therapeutic Target in ALL

Julia Dudkiewicz, MD¹^*, Filip Garbicz²^* and Pawel Krzysztof Wlodarski, MD, PhD¹^*

¹Medical University of Warsaw Center for Biostructure Research, Warsaw, Poland
²Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland

2267

Preclinical Efficacy and Mechanism for a Novel BTK-Protacs Against Mantle Cell Lymphoma

Yue Fei¹^*, Xiaohui Wang¹^*, Shangzhe Yu²^*, Yixin Yao, PhD³, Guisen Zhao²^*, Xianhuo Wang¹^* and Huilai Zhang, MD¹^*

¹Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
²Shandong University, Jinan, China
³Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

802.P1.27 802. Chemical Biology and Experimental Therapeutics: Poster I